COPD statistics quick reference¶
Last curated: 2026-09-02
Prevalence and burden¶
| Figure | Source/year | Population | Method |
|---|---|---|---|
| 391.9 million people; 10.3% prevalence | Adeloye 2022, PMID 35279265 | Adults 30–79, global, 2019 | Systematic review and modeling; fixed FEV1/FVC |
| Global/regional prevalence estimates | Adeloye 2015, PMID 26755942 | Population spirometry studies | Systematic review/meta-analysis |
| Burden in 195 countries, 1990–2017 | GBD CRD 2020, PMID 32526187 | Global | GBD comparative modeling |
| Burden and attributable risks in 204 countries, 1990–2019 | Safiri 2022, PMID 35896191 | Global | GBD 2019 modeling |
| COPD burden projection through 2050 | Boers 2023, PMID 38060225 | Global | Demographic/risk projection |
| GOLD stage II+ prevalence 10.1% overall; 11.8% men; 8.5% women | Buist 2007, PMID 17765523 | 9,425 adults, 12 BOLD sites | Standardized post-bronchodilator population survey |
| Stage II+ COPD OR 1.94 (95% CI 1.80–2.10) per decade of age | Buist 2007, PMID 17765523 | BOLD sites | Pooled logistic models |
| COPD prevalence 7.8% (95% CI 5.9–9.7) in Mexico City to 19.7% (17.2–22.2) in Montevideo | Menezes 2005, PMID 16310554 | Adults ≥40 in five Latin-American cities | PLATINO probability samples; post-BD fixed ratio |
| São Paulo COPD prevalence 15.8% (95% CI 13.5–18.1) | Menezes 2005, PMID 16158163 | Adults >40, metropolitan São Paulo | PLATINO probability sample; post-BD fixed ratio |
| Never-smoker COPD 10.5% (95% CI 9.1–12.1) by fixed ratio versus 4.6% by LLN | Ivey 2024, PMID 38249822 | 1,656 never-smokers aged ≥40, BOLD Australia | Cross-sectional post-BD spirometry |
| COPD prevalence 8.2%; men 12.4%, women 5.1%; 35.3% asymptomatic; 6.5% previously tested by spirometry | Zhong 2007, PMID 17575095 | 20,245 adults aged ≥40 across seven Chinese regions | Population survey; post-BD fixed ratio; 79.0% response |
Diagnostic and natural-history figures¶
| Figure | Source/year | Population | Method |
|---|---|---|---|
| Fixed post-BD FEV1/FVC <0.70 is the operational GOLD obstruction criterion | Vestbo 2013, PMID 22878278 | Clinical COPD evaluation | Strategy synthesis |
| Prior exacerbation predicts future susceptibility | Hurst 2010, PMID 20843247 | ECLIPSE longitudinal cohort | Prospective event follow-up |
| US PRISm and COPD have separable prevalence/mortality risk | Cadham 2024, PMID 38750492 | NHANES 2007–2012 | Population cohort linkage |
| COPD after 22 years: 26% with FEV1 <80% predicted before 40 versus 7% with preserved early FEV1 | Lange 2015, PMID 26154786 | Three longitudinal cohorts | Trajectory analysis |
| Approximate mean FEV1 decline 53±21 mL/year in normal-attainment/rapid-decline COPD versus 27±18 mL/year in low-attainment COPD | Lange 2015, PMID 26154786 | Three longitudinal cohorts | Retrospective trajectory grouping |
| Normal-attainment/rapid-decline versus low-attainment COPD: all-cause mortality HR 1.93 (95% CI 1.14–3.26) | Marott 2020, PMID 32289231 | Copenhagen City Heart Study | Longitudinal cohort |
| Terminal bronchioles reduced 72–89%; total cross-sectional area reduced 81–99.7% in GOLD 4 explants | McDonough 2011, PMID 22029978 | COPD transplant explants versus donor controls | Micro-CT and CT pathology |
| Persistent systemic inflammation: mortality 13% versus 2%; exacerbations 1.5 versus 0.9/year | Agustí 2012, PMID 22624038 | 1,755 ECLIPSE COPD participants | Three-year biomarker cohort |
| CT mucus plugs: mortality 34.0%, 46.7%, 54.1% for 0, 1–2, ≥3 plugged segments | Diaz 2023, PMID 37210745 | 4,363 COPDGene participants; median 9.5 years | Adjusted observational cohort |
| Fixed-ratio outcome optimum 0.71; C-statistic difference versus 0.70, 0.001 (95% CI −0.002 to 0.004) | Bhatt 2019, PMID 31237643 | 24,207 adults; 3,925 COPD hospitalizations/deaths over median 15 years | Four pooled US cohorts; prognostic discrimination, not diagnostic adjudication |
| Case-finding plus specialist/educator care: respiratory-use IRR 0.48 (95% CI 0.36–0.63); FEV1 difference +94 mL (50–138) | Aaron 2024, PMID 38767248 | 508 symptomatic adults with newly diagnosed asthma or COPD | One-year randomized care-pathway trial |
| Each SD greater CT Pi10: incident COPD OR 2.22 (95% CI 1.43–3.45); respiratory hospitalization/death risk +57% | Oelsner 2018, PMID 29529382 | 1,830 MESA adults without baseline chronic lower-respiratory disease | Adjusted population cohort; 78,147 person-years |
Treatment effects and boundaries¶
| Finding | Source/year | Population | Method |
|---|---|---|---|
| Smoking intervention reduced 14.5-year all-cause mortality | Anthonisen 2005, PMID 15710956 | Smokers with mild/moderate obstruction | Randomized intervention follow-up |
| LABA/LAMA reduced exacerbations versus LABA/ICS in FLAME | Wedzicha 2016, PMID 27181606 | Exacerbation-risk COPD | 52-week RCT |
| Triple therapy reduced moderate/severe exacerbations but increased pneumonia versus LABA/LAMA in IMPACT | Lipson 2018, PMID 29668352 | Symptomatic exacerbation-prone COPD | 52-week RCT |
| ETHOS higher-dose triple reduced exacerbations versus dual comparators | Rabe 2020, PMID 32579807 | Moderate-to-very severe COPD with event history | 52-week RCT |
| Azithromycin reduced exacerbations over one year with hearing/resistance concerns | Albert 2011, PMID 21864166 | Selected high-risk COPD | RCT |
| PR improves exercise capacity and health-related quality of life | McCarthy 2015, PMID 25705944 | Stable COPD trials | Cochrane review |
| Continuous oxygen improved survival versus nocturnal oxygen in severe hypoxemia | NOTT 1980, PMID 6776858 | Severe chronic hypoxemic COPD | RCT |
| Oxygen did not improve death/first hospitalization in moderate resting/exercise desaturation | Albert 2016, PMID 27783918 | Stable moderate desaturation | RCT |
| Home NIV plus oxygen prolonged time to readmission/death | Murphy 2017, PMID 28528348 | Persistent hypercapnia after life-threatening event | RCT |
| Zephyr valves improved lung function, exercise and health status with pneumothorax risk | Criner 2018, PMID 29787288 | Heterogeneous emphysema, no collateral ventilation | RCT |
| Dupilumab reduced annualized moderate/severe exacerbations in eosinophilic chronic-bronchitis COPD | Bhatt 2023, PMID 37272521 | Eosinophils ≥300/µL despite triple therapy | Phase 3 RCT |
| Dupilumab result replicated | Bhatt 2024, PMID 38767614 | Similar selected population | Phase 3 RCT |
| Tiotropium maintained 87–103 mL pre-BD FEV1 advantage but did not alter post-day-30 decline | Tashkin 2008, PMID 18836213 | 5,993 participants over four years | UPLIFT RCT |
| Tiotropium versus salmeterol: first exacerbation HR 0.83 (95% CI 0.77–0.90); severe-event rate ratio 0.73 (0.66–0.82) | Vogelmeier 2011, PMID 21428765 | 7,376 exacerbation-risk participants | POET-COPD RCT |
| ICS withdrawal: first moderate/severe exacerbation HR 1.06 (95% CI 0.94–1.19); trough FEV1 −43 mL at week 52 | Magnussen 2014, PMID 25196117 | 2,485 severe COPD participants after triple run-in | WISDOM non-inferiority RCT |
| Five versus 14 days prednisone: re-exacerbation difference −1.2 points (95% CI −12.2 to 9.8); cumulative dose 379 versus 793 mg | Leuppi 2013, PMID 23695200 | 314 acute exacerbations, 92% hospitalized | REDUCE non-inferiority RCT |
| Eosinophil-guided acute steroids: median 2 versus 5 days; 30-day failure 26% versus 26% | Sivapalan 2019, PMID 31122894 | 318 hospitalized exacerbations | CORTICO-COP non-inferiority RCT |
| Home versus centre PR at completion: 6MWD +18.6 m (95% CI −3.3 to 40.7); gains not maintained at 12 months | Holland 2017, PMID 27672116 | 166 stable COPD participants | Equivalence RCT |
| Supported self-management reduced COPD admissions 39.8% and emergency visits 41.0% | Bourbeau 2003, PMID 12622605 | Advanced COPD with prior admission | Multicenter RCT |
| Severe-hypoxemia oxygen: five-year deaths 19/42 versus 30/45 | MRC Working Party 1981, PMID 6110912 | Severe hypoxemia/cor pulmonale | Controlled randomized trial |
| CO2-targeted NIV: one-year mortality 12% versus 33%; HR 0.24 (95% CI 0.11–0.49) | Köhnlein 2014, PMID 25066329 | Stable GOLD 4 COPD, PaCO2 ≥51.9 mm Hg | Multicenter RCT |
| NETT overall mortality RR 1.01; upper-lobe/low-exercise RR 0.47; non-upper-lobe/high-exercise RR 2.06 | Fishman 2003, PMID 12759479 | 1,218 severe emphysema participants after PR | LVRS RCT with subgroup interaction |
| TRANSFORM ≥12% FEV1 response 55.4% versus 6.5%; 6MWD difference +78.7 m | Kemp 2017, PMID 28885054 | Heterogeneous emphysema without collateral ventilation | Valve RCT |
| Ensifentrine FEV1 AUC +87 mL (95% CI 55–119) and +94 mL (65–124); event rate ratios 0.64 and 0.57 | Anzueto 2023, PMID 37364283 | 760 and 789 moderate/severe COPD participants | Replicate ENHANCE phase 3 RCTs |
| Mepolizumab 0.80 versus 1.01 moderate/severe events/year; rate ratio 0.79 (95% CI 0.66–0.94) | Sciurba 2025, PMID 40305712 | Eosinophils ≥300/µL despite triple therapy | MATINEE phase 3 RCT |
| SUMMIT mortality HR 0.88 (95% CI 0.74–1.04); cardiovascular composite HR 0.93 (0.75–1.14) | Vestbo 2016, PMID 27203508 | 16,485 moderate-COPD participants with cardiovascular risk | Four-arm RCT |
| Nocturnal oxygen: death/progression to LTOT 39.0% versus 42.0%; difference −3.0 points (95% CI −15.1 to 9.1) | Lacasse 2020, PMID 32937046 | 243 with isolated nocturnal desaturation | Under-recruited sham-controlled RCT |
| Post-acute NIV: readmission/death 65% versus 64% at one year despite PaCO2 improvement | Struik 2014, PMID 24781217 | 201 with hypercapnia >48 h after ventilatory support | RCT |
| Procalcitonin protocols: antibiotic prescribing RR 0.56 (95% CI 0.43–0.73); mortality RR 0.99 (0.58–1.69) | Mathioudakis 2017, PMID 28143877 | 1,062 exacerbations in eight trials | Meta-analysis; low/moderate certainty |
| Telerehabilitation versus center PR: 6MWD MD 0.06 m (95% CI −10.82 to 10.94); completion 93% versus 70% | Cox 2021, PMID 33511633 | 1,904 participants in 15 studies; 99% COPD | Cochrane synthesis |
| ICS-containing versus non-ICS inhaled therapy mortality OR 0.90 (95% CI 0.84–0.97); triple therapy OR 0.73 (0.59–0.91) | Chen 2023, PMID 35921883 | 103,034 participants in 60 RCTs | Meta-analysis; subgroup and comparator-selection caveats |
| Early supervised post-exacerbation PR mortality RR 0.58 (95% CI 0.35–0.98); readmission RR 0.47 (0.29–0.75) | Ryrsø 2018, PMID 30219047 | 801 participants in 13 RCTs | Meta-analysis; mortality based on four trials/319 participants |
| Ambulatory oxygen: 56% achieved clinically important short-term CRQ response, but 41% of acute/short-term responders declined continuation | Eaton 2002, PMID 12212960 | 41 non-chronically-hypoxemic participants with exertional SpO2 ≤88% | 12-week double-blind crossover RCT |
| RENEW coils: 6MWD difference +14.6 m; ≥25-m responders 40.0% versus 26.9%; SGRQ difference −8.9 points | Sciurba 2016, PMID 27179849 | 315 severe-emphysema participants | Randomized trial; benefit below mean 6MWD MCID with procedural harms |
| Metoprolol: first-exacerbation HR 1.05 (95% CI 0.84–1.32); hospitalized exacerbation HR 1.91 (1.29–2.83) | Dransfield 2019, PMID 31633896 | 532 exacerbation-prone patients without cardiac beta-blocker indication | Early-stopped placebo-controlled RCT |
| Itepekimab exacerbation RR 0.81 (95% CI 0.61–1.07) overall; former-smoker subgroup RR 0.58 (0.39–0.85) | Rabe 2021, PMID 34302758 | 343 moderate-to-severe COPD participants | Phase 2a RCT; overall primary endpoint not met |
| Astegolimab exacerbation rate ratio 0.78 (95% CI 0.53–1.14; p=0.19) | Yousuf 2022, PMID 35339234 | Moderate-to-very-severe COPD | Phase 2a RCT; primary endpoint not met |
Multidimensional outcomes and systemic burden¶
| Figure | Source/year | Population | Method |
|---|---|---|---|
| BODE all-cause mortality HR 1.34 (95% CI 1.26–1.42) per point; C statistic 0.74 versus 0.65 for FEV1 | Celli 2004, PMID 14999112 | 625-person prospective validation cohort | Multidimensional prognostic index |
| COTE ≥4 associated with approximately 2.2-fold mortality risk across BODE quartiles | Divo 2012, PMID 22561964 | 1,664 COPD participants; 79 comorbidities recorded | Prospective multicenter cohort |
| Cardiovascular event HR 3.8 (95% CI 2.7–5.5) in 30 days after exacerbation; HR 9.9 (6.6–14.9) after hospitalized event | Kunisaki 2018, PMID 29442524 | 16,485 SUMMIT participants with CVD/risk | Post hoc adjudicated cohort analysis |
| Frailty prevalence 32.07% (95% CI 26.64–37.49); mortality HR 1.68 (1.37–2.05); 6MWD −90.23 m | Wang 2023, PMID 37173728 | 20 studies, 11,620 participants | Systematic review/meta-analysis |
| Osteoporosis prevalence 38% (95% CI 34–43); COPD OR 2.83; low BMI OR 4.26; sarcopenia OR 3.65 | Chen 2019, PMID 31352034 | 58 studies | Systematic review/meta-analysis |
| Cardiovascular events after severe exacerbation, days 1–14: HR 14.5 (95% CI 12.2–17.3) | Graul 2024, PMID 38127850 | 213,466 people with COPD in England | Linked population cohort |
| Lung-cancer risk after COPD: RR 2.22 (95% CI 1.66–2.97); never-smoker restricted combined estimate 1.22 (0.97–1.53) | Brenner 2011, PMID 21483846 | 16 COPD studies within a systematic review | Random-effects meta-analysis |
| Fibrinogen ≥350 mg/dL: hospitalized-exacerbation HR 1.64 (95% CI 1.39–1.93), mortality HR 1.94 (1.62–2.31) | Mannino 2015, PMID 25685850 | 6,376 pooled COPD participants | Prognostic/enrichment analysis |
| Proteobacteria-dominant sputum microbiome mortality HR 2.58 (95% CI 1.43–4.66) versus Firmicutes dominance | Dicker 2021, PMID 32353489 | 253 stable COPD participants; median four-year follow-up | 16S cohort; association, not causal effect |
| Doubling fibrinogen mortality HR 2.2 (95% CI 1.3–3.7); adding it to MR-proADM did not improve AUC (0.83 vs 0.82; p=0.34) | Zuur-Telgen 2021, PMID 34886719 | 640 stable and 262 hospitalized COPD participants | Three-year cohort; incremental-prediction analysis |
Safety signals¶
| Signal | Source/year | Population | Method |
|---|---|---|---|
| ICS increases pneumonia risk; magnitude varies by molecule/dose | Zhang 2020, PMID 32643439 | COPD RCTs | Meta-analysis |
| Pneumothorax is a major early endobronchial-valve hazard | Criner 2018, PMID 29787288 | LIBERATE | RCT safety outcome |
| Low-dose extended-release morphine did not show uniform chronic-breathlessness benefit | Ekström 2022, PMID 36413230 | COPD with chronic breathlessness | BEAMS RCT |
| TRANSFORM pneumothorax 19/65 treated participants (29.2%) | Kemp 2017, PMID 28885054 | Selected heterogeneous emphysema | Valve RCT |
| WISDOM ICS withdrawal reduced trough FEV1 by 43 mL at week 52 despite exacerbation non-inferiority | Magnussen 2014, PMID 25196117 | Severe COPD after triple run-in | RCT harm/tradeoff |
| Pulmonary embolism prevalence 12% (95% CI 9–16%); mortality OR 5.30 (2.48–11.30) | Sato 2021, PMID 34879475 | 4,093 acute exacerbations in 16 studies | Protocolized-study meta-analysis; I2 94.8% |
| Pulmonary embolism 11% (95% CI 6–17%) and DVT 9% (6–12%) during acute exacerbation | Han 2022, PMID 35355978 | 5,854 participants in 20 studies | Systematic review/meta-analysis; ascertainment timing varied |
| Troponin elevation during hospitalized exacerbation: all-cause mortality OR 1.69 (95% CI 1.25–2.29) | Pavasini 2015, PMID 25965630 | Eight-study meta-analysis | Adjusted prognostic associations; myocardial-injury mechanisms heterogeneous |
Known conflicts and caveats¶
- Prevalence estimates differ by fixed ratio versus LLN, pre- versus post-bronchodilator testing, age range and survey access; do not average them.
- GBD results are modeled estimates, not direct global spirometry counts.
- Trial populations are enriched and underrepresent never-smokers, lower-resource settings, frailty and multimorbidity.
- Secondary mortality analyses in triple-therapy trials require caution because of prior ICS withdrawal and multiple testing.
- Short-term physiological improvement does not imply survival or admission benefit.
- Registry status and burden projections are dated snapshots.
- Subgroup effects such as NETT's mortality interaction are credible only when the interaction and biological selection are considered; they must not be generalized to all severe emphysema.
- Non-inferiority results depend on the prespecified margin: “non-inferior” is not “identical.”
- Biomarker-enriched trials estimate effects in the enriched population; they do not validate the cutoff as a universal biological boundary.